安罗替尼二线治疗晚期非小细胞肺癌的临床疗效分析

Analysis of the Clinical Efficacy of Anlotinib in the Second-line Treatment of Advanced Non-small Cell Lung Cancer

目的观察安罗替尼二线治疗晚期非小细胞肺癌的疗效。方法选取2018年6月—2019年12月晚期非小细胞肺癌患者60例,将其分为安罗替尼治疗研究组和最佳支持治疗对照组,每组30例。组间对比无进展生存时间和总生存时间、临床有效率和疾病控制率,并观察研究组的不良反应情况。结果研究组有效率为26.70%,高于对照组0.00%(χ^2=9.231,P=0.002);研究组疾病控制率为76.70%,高于对照组30.00%(χ^2=13.125,P<0.001);研究组无进展生存时间为(4.33±1.26)个月,长于对照组(1.98±0.89)个月,研究组总生存时间为(8.89±2.22)个月,长于对照组(5.39±1.11)个月,差异有统计学意义(t=8.344、7.724,P<0.05)。研究组患者虽有发生疲乏、腹泻、高血压、甲状腺功能减退等不良反应,但均不严重,且在下调剂量或者对症处理后均能缓解。结论安罗替尼二线治疗晚期非小细胞肺癌有较好的临床效果,且不良反应较轻,耐受性良好,临床可以通过安罗替尼二线治疗为晚期非小细胞肺癌患者延长生存时间。

Objective To observe the efficacy of Anlotinib in the second-line treatment of advanced non-small cell lung cancer.Methods Sixty patients with advanced non-small cell lung cancer from June 2018 to December 2019 were selected and divided into anlotinib treatment study group and best supportive treatment control group,with 30 cases in each group.The progression-free survival time and overall survival time,clinical effective rate and disease control rate were compared between the groups,and the adverse reactions of the study group were observed.Results The effective rate of the study group was 26.70%,0.00%higher than the control group(χ^2=9.231,P=0.002);the disease control rate of the study group was 76.70%,30.00%higher than the control group(χ^2=13.125,P<0.001);study group of the progression-free survival time was(4.33±1.26)months,which was(1.98±0.89)months longer than the control group;the overall survival time of the study group was(8.89±2.22)months,which was(5.39±1.11)months longer than the control group,the difference was statistically significant(t=8.344,7.724,P<0.05).Although the patients in the study group had adverse reactions such as fatigue,diarrhea,hypertension,and hypothyroidism,they were not serious and could be relieved after lowering the dose or symptomatic treatment.Conclusion Anlotinib has a good clinical effect in the second-line treatment of advanced non-small cell lung cancer,and the side effects are mild,and it is well tolerated.Clinically,anlotinib can be used to prolong the survival time of patients with advanced non-small cell lung cancer.